Anticoagulation and monitoring of a novel and reversible factor IXa inhibitor

Journal Article (Review;Journal)

Clinical Development Phases I-III Regulatory, Quality, Manufacturing Thrombosis as a clinical phenotype is ubiquitous in human diseases and conditions, ranging from atherosclerosis and other vascular disorders to trauma, surgery, malignancy, infections, blood dyscrasias, auto-immunity, and complications of pregnancy. While each condition carries its own distinct signature and predisposition for thrombosis as a nonphysiological event, there are several common themes that center on cellular and noncellular elements, including well-characterized coagulation proteases. Over the past decade, our group has been actively involved with the development of a factor IXa inhibitor, pegnivacogin, and its complementary antidote or control agent, anivamersen. The following review provides a summary of fundamental constructs, milestones, and the current status of our translational journey. © 2013 Wiley Periodicals, Inc.

Full Text

Duke Authors

Cited Authors

  • Becker, RC; Chan, MY; Vavalle, JP; Povsic, TJ

Published Date

  • December 1, 2013

Published In

Volume / Issue

  • 74 / 8

Start / End Page

  • 510 - 516

Electronic International Standard Serial Number (EISSN)

  • 1098-2299

International Standard Serial Number (ISSN)

  • 0272-4391

Digital Object Identifier (DOI)

  • 10.1002/ddr.21109

Citation Source

  • Scopus